The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > ACADEMIA
ACADEMIA
- NCC Hospital Crafting Scheme to Offer Off-Label Meds after Genomic Profiling
July 23, 2019
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- Japanese Data More Positive for Keytruda’s Frontline Use in Gastric Cancer
July 22, 2019
- Keytruda Shows Promise in Japanese HCC Patients despite Global Miss
July 22, 2019
- Keytruda Slashes Death Risk by 78% in Japanese Head and Neck Cancer Patients
July 19, 2019
- New Pancreatic Cancer Guidelines Recommend FOLFIRINOX as 1st-Line Therapy
July 19, 2019
- TMDU, Tokyo Govt Join Hands for Open Innovation in Drug Discovery, Healthcare
July 18, 2019
- Virologist Expresses Concern over Spread of Resistant Flu Viruses to Xofluza
July 17, 2019
- Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
- NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
- Gynecologist Stresses Urgent Need to Resume HPV Vaccinations, Cites Age Disparity in Cervical Cancer Risk
July 10, 2019
- Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
- Univ. of Tokyo, 3H to Start Matching Program for Rare Disease R&D
May 21, 2019
- Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
May 17, 2019
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
- Nobel Laureate Honjo Says Rewards for Opdivo Patent Too Small
April 12, 2019
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…